A phase II clinical trial of frameless fractionated stereotactic radiotherapy for brain metastases
Mené sur 73 patients présentant des métastases cérébrales (âge médian : 68 ans ; durée médiane de suivi : 10 mois), cet essai de phase II évalue l'efficacité, du point de vue de la survie, d'une radiothérapie stéréotaxique fractionnée sans cadre
Stereotactic radiotherapy (SRT) yields high rates of local control for brain metastases, but rural/suburban patients face geographic and socioeconomic barriers to access SRT. We conducted a Phase 2 clinical trial of frameless fractionated stereotactic radiotherapy (FFSRT) for brain metastases in an integrated academic satellite network for patients ≥18-years-old with 1-4 brain metastases. Dose was based on gross tumor volume (GTV) size: < 3.0 cm, 27 Gy in 3 fractions, and 3.0-3.9 cm, 30 Gy in 5 fractions. Median follow-up was 10 months for 73 evaluable patients with median age of 68 years. Median intracranial progression free survival (PFS) was 7.1 months (95% confidence interval (CI): 5.3-not reached (NR)), median survival 7.2 months (95% CI: 5.4-NR), and there were no severe adverse events. Outcomes of this trial compare favorably with contemporary trials and this treatment strategy provides opportunities to expand SRT access to underserved populations.
JNCI Cancer Spectrum 2023